Samsung Bioepis selects UK as EU biosimilar base; no comment on IPO plan

By Gareth Macdonald contact

- Last updated on GMT

Samsung Bioepis to manage European biosimilars business from UK
Samsung Bioepis to manage European biosimilars business from UK

Related tags: Samsung bioepis, Etanercept

Samsung Bioepis will base its European operations in the UK at an entity set up to hold marketing authorizations for biosimilars it has filed for EMA review.

The  Incheon, Korea headquartered firm – a joint venture between South Korean conglomerate Samsung and Switzerland’s Biogen – is seeking approval for a number of biosimilars in various markets, including Europe.

Last month, the European Medicines Agency’s (EMA) Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended that Benepali, a biosimilar version of Amgen’s Enbrel (etanercept), be approved in Europe.

Spokesman Mingi Hyun told us: "Samsung Bioepis UK was established to support our operations in Europe.”

He added that: “One of SBUK's primary responsibilities will be to act as Samsung Bioepis' market authorization holder (MAH) upon approval of our biosimilar products in the European Union​."

However, if Benepali or any of the other biosimilars Samsung Bioepis is developing is approved by European regulators, Biogen will be responsible for selling it according to spokeswoman Shannon Altimari.

She confirmed that: “Bioepis is the MAH for all the anti-TNF biosimilars we partner on here in Europe. Biogen is the commercialization leads here for all three anti-TNFs, Benepali, SB2 and SB5​.”

Complex commercialization deal  

Biogen will also sell the Enbrel biosimilar in Switzerland, and Japan, while Merck & Co. (known as MSD outside North America) will commercialise the biosimilar in all other markets, excluding the US.

The drug was recently approved​ in Korea and Merck & Co is expected to launch it​ before the end of the year.

Merck will also be responsible for selling Renflexis​, Samsun Bioepis's  biosimilar version of J&J’s Remicade (infliximab), in Korea.

Merck & Co sells the originator drug in Europe, Russia and Turkey under a 2011 deal with J&J.

IPO: no comment

In July​ Samsung Bioepis told us it was considering an IPO on the NASDAQ Stock Exchange to raise cash to fund the development of biosimilar products.

We asked the firm if the plan is still on track, however, a spokesman told us “We are unable to comment at this time.​"

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us

Products

View more

Webinars